Table 1.
Parameters | TAF 25 mg | TDF 300 mg | ETV 0.5 mg | P value |
---|---|---|---|---|
(n = 10) | (n = 10) | (n = 20) | ||
Age (years) | 40.56 ± 11.18 | 41.00 ± 12.64 | 39.72 ± 9.13 | 0.901 |
Male, n (%) | 10 (100) | 10 (100) | 20 (100) | 1.0 |
Liver cirrhosis | 8 (80) | 7 (70) | 13 (65) | 0.901 |
ALT (U/L) | 351.10 (308.72) | 203.67 (173.61) | 385.85 (519.33) | 0.588 |
AST (U/L) | 263.78 (242.47) | 156.89 (84.39) | 382.61 (397.06) | 0.707 |
TBIL (μmol/L) | 362.93 (178.62) | 321.10 (127.87) | 240.44 (144.35) | 0.174 |
Albumin (g/L) | 31.32 (3.71) | 30.90 (4.38) | 32.23 (4.19) | 0.905 |
Urea (mmol/L) | 5.71 (3.09) | 5.74 (2.70) | 5.86 (3.23) | 0.948 |
Creatinine (μmol/L) | 77.22 (34.20) | 66.22 (22.08) | 66.00 (24.27) | 0.458 |
eGFR (mL/min/1.73m2) | 112.76 (41.47) | 150.23 (30.12) | 112.34 (68.85) | 0.274 |
INR | 1.71 (0.32) | 2.08 (0.87) | 2.13 (0.63) | 0.179 |
WBC (× 109/L) | 6.22 (1.82) | 7.28 (3.48) | 6.91 (3.54) | 0.819 |
PLT (×109/L) | 115.11 (60.48) | 97.44 (113.02) | 98.33 (63.09) | 0.168 |
Serum sodium, mmol/L | 137.11 (2.32) | 135.11 (4.96) | 135.16 (7.06) | 0.784 |
HbeAg positive | 8 (80) | 8 (80) | 15 (75) | 0.931 |
LogHBV DNA (log IU/mL) | 4.80 (1.93) | 5.81 (1.87) | 5.13 (1.89) | 0.458 |
MELD score | 21.56 (5.66) | 21.33 (7.28) | 20.50 (5.40) | 0.943 |
CTP score | 10.22 (1.44) | 10.78 (1.64) | 10.44 (1.56) | 0.151 |
CTP class(B/C) | 3/7 | 1/9 | 1/19 | 0.202 |
NUC-naïve | 7 (70) | 2 (20) | 15 (75) | 0.019 |
Follow-up (wk) | 68.50 (48–92) | 64.50 (51–95) | 69.00 (50–95) | 0.938 |
Data are expressed as mean ± standard deviation (SD), number (percentage) or median (range)
ETV entecavir, TDF tenofovir disoproxil fumarate, TAF tenofovir alafenamide, ALT alanine aminotransferase, AST aspartate Aminotransferase, TBIL total bilirubin, INR international normalized ratio, WBC white blood cell count, PLT platelet count, HBeAg Hepatitis B e antigen, HBV hepatitis B virus, MELD Model for End-stage Liver Disease, CTP Child-Turcotte-Pugh, NUC nucleos(t) ide analogues